This article is more than 5 years old. Information may no longer be current.
VIDEO: NSABP B-52 may set stage for ‘interesting correlative studies’
Click Here to Manage Email Alerts
SAN ANTONIO — Adam M. Brufsky, MD, PhD, co-director of the Comprehensive Breast Cancer Center at University of Pittsburgh and a HemOnc Today Editorial Board member, spoke with HemOnc Today about the potential impact of the NSABP B-52 trial.
The trial— results of which were presented at San Antonio Breast Cancer Symposium — evaluated the addition of estrogen deprivation to neoadjuvant chemotherapy for patients with ER– and HER-2–positive breast cancer.
The combination increased pathologic complete response rates numerically, but the improvement did not reach statistical significance.
Brufsky noted an interest among physicians to treat this patient population with neoadjuvant regimens that do not include chemotherapy.
“That’s an important thing that a lot of investigators are exploring, so we may see more data on this in the coming months to years,” Brufsky said. “They also took a lot of samples during this trial, so there are some very interesting correlative studies that we may be able to do to understand the interplay between the ER and HER-2 pathways in the neoadjuvant therapy of breast cancer.” – by Kristie L. Kahl
Reference:
Rimawi MF, et al. Abstract s3-06. Presented at: San Antonio Breast Cancer Symposium; Dec. 7-9, 2016; San Antonio, Texas.
Disclosure: Brufsky reports no relevant financial disclosures.